JOURNAL DESCRIPTION
The Medical Radiology and Radiation Safety journal ISSN 1024-6177 was founded in January 1956 (before December 30, 1993 it was entitled Medical Radiology, ISSN 0025-8334). In 2018, the journal received Online ISSN: 2618-9615 and was registered as an electronic online publication in Roskomnadzor on March 29, 2018. It publishes original research articles which cover questions of radiobiology, radiation medicine, radiation safety, radiation therapy, nuclear medicine and scientific reviews. In general the journal has more than 30 headings and it is of interest for specialists working in thefields of medicine¸ radiation biology, epidemiology, medical physics and technology. Since July 01, 2008 the journal has been published by State Research Center - Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency. The founder from 1956 to the present time is the Ministry of Health of the Russian Federation, and from 2008 to the present time is the Federal Medical Biological Agency.
Members of the editorial board are scientists specializing in the field of radiation biology and medicine, radiation protection, radiation epidemiology, radiation oncology, radiation diagnostics and therapy, nuclear medicine and medical physics. The editorial board consists of academicians (members of the Russian Academy of Science (RAS)), the full member of Academy of Medical Sciences of the Republic of Armenia, corresponding members of the RAS, Doctors of Medicine, professor, candidates and doctors of biological, physical mathematics and engineering sciences. The editorial board is constantly replenished by experts who work in the CIS and foreign countries.
Six issues of the journal are published per year, the volume is 13.5 conventional printed sheets, 88 printer’s sheets, 1.000 copies. The journal has an identical full-text electronic version, which, simultaneously with the printed version and color drawings, is posted on the sites of the Scientific Electronic Library (SEL) and the journal's website. The journal is distributed through the Rospechat Agency under the contract № 7407 of June 16, 2006, through individual buyers and commercial structures. The publication of articles is free.
The journal is included in the List of Russian Reviewed Scientific Journals of the Higher Attestation Commission. Since 2008 the journal has been available on the Internet and indexed in the RISC database which is placed on Web of Science. Since February 2nd, 2018, the journal "Medical Radiology and Radiation Safety" has been indexed in the SCOPUS abstract and citation database.
Brief electronic versions of the Journal have been publicly available since 2005 on the website of the Medical Radiology and Radiation Safety Journal: http://www.medradiol.ru. Since 2011, all issues of the journal as a whole are publicly available, and since 2016 - full-text versions of scientific articles. Since 2005, subscribers can purchase full versions of other articles of any issue only through the National Electronic Library. The editor of the Medical Radiology and Radiation Safety Journal in accordance with the National Electronic Library agreement has been providing the Library with all its production since 2005 until now.
The main working language of the journal is Russian, an additional language is English, which is used to write titles of articles, information about authors, annotations, key words, a list of literature.
Since 2017 the journal Medical Radiology and Radiation Safety has switched to digital identification of publications, assigning to each article the identifier of the digital object (DOI), which greatly accelerated the search for the location of the article on the Internet. In future it is planned to publish the English-language version of the journal Medical Radiology and Radiation Safety for its development. In order to obtain information about the publication activity of the journal in March 2015, a counter of readers' references to the materials posted on the site from 2005 to the present which is placed on the journal's website. During 2015 - 2016 years on average there were no more than 100-170 handlings per day. Publication of a number of articles, as well as electronic versions of profile monographs and collections in the public domain, dramatically increased the number of handlings to the journal's website to 500 - 800 per day, and the total number of visits to the site at the end of 2017 was more than 230.000.
The two-year impact factor of RISC, according to data for 2017, was 0.439, taking into account citation from all sources - 0.570, and the five-year impact factor of RISC - 0.352.
Issues journals
Medical Radiology and Radiation Safety. 2021. Vol. 66. № 5. P. 50–58
Role of Intensification of Neoadjuvant Treatment of Patients with Locally Expanded Rectal Cancer
A.V. Polynovsky1, D.V. Kuzmichev1, Z.Z. Mamedli1, S.I. Tkachev1, M.V. Chernykh1, Yu.E. Suraeva2, Zh.M. Madyarov1, A.A. Aniskin2, E.S. Kolobanov 3
1N.N. Blokhin National Medical Research Center of Oncology, Moscow, Russia
2Research Institute of Healthcare Organization and Medical Management of the Moscow Department of Healthcare, Moscow, Russia
3PET-Technology, Podolsk, Moscow Region, Russi
Contact person: Andrey Vladimirovich Polynovsky: This email address is being protected from spambots. You need JavaScript enabled to view it.
ABSTRACT
Purpose: To improve the effectiveness of treatment of patients with locally advanced rectal cancer (LARC) stage T3(MRF+)-4N0-2M0 by developing a new strategy of therapy.
Material and methods: The study included 414 patients with LARC. Control group I included 89 patients who underwent neoadjuvant CRT 52–56 Gy with capecitabine. Control group II included 160 patients, underwent neoadjuvant CRT 52–56 Gy with capecitabine and oxaliplatin once a week, during the course of RT. Study group III - 165 patients. This group combined neoadjuvant CRT 52–56 Gy with capecitabine and additional consecutive courses of chemotherapy (CT) in the CapOx mode. This group, depending on the variant of chemotherapy, was divided into 2 subgroups: subgroup IIIa included 106 patients with consolidating CT (after CRT); subgroup IIIb included 59 patients who underwent "sandwich" treatment. Therapy consists of conducting 1 or 2 courses of induction CT (up to CRT) in the CapOx mode and 1 or 2 courses of consolidating CT in the CapOx mode with an interval of 7 days. In the interval between the courses of drug therapy, prolonged CRT was performed. According to the results of the control examination, further treatment tactics were determined.
Results: IComplete therapeutic pathomorphosis in the tumor was significantly more frequently registered in patients in the study group III (17.5 %; p=0.021) compared to the control groups: in I – 8.0 % and II – 8.3 %. In total, relapses in the study were registered in 34 (8.3 %) of 410 patients. A comparative analysis of patients in the control groups (I and II) of treatment did not determine significant differences in the development of relapses (11.4 % vs. 10.8 %, respectively; p=0.884). When analyzing the subgroups (IIIa and IIIb) of the study group, there were also no significant differences in the development of relapses (4.8 % vs. 3.4 %; p=0.676). In the present study, long-term metastases at various times after treatment were diagnosed in 100 (24.4 %) of 410 patients. All metastases occurred at a median follow-up of 20.9 months (4 to 46 months). Metastases were significantly less frequent in patients in group III (18.3 %) compared to group I (31.8 %; p=0.015) and II (26.6 %; p=0.037). There were no significant differences between patients in group I and II (p=0.382). The analysis of the treatment subgroups of the study group (IIIa and IIIb) did not determine significant differences in the development of metastases (19.1 % vs. 17.0 %; p=0.456). The overall five-year survival rate in patients in group III was 90.5 %, in group I – 71.8% and in group II – 78.3%. Five-year relapse-free survival in patients in the study groups was: III – 71.5%, I – 56.9% and II – 65.6%, respectively.
Conclusion: The shift in the focus on strengthening the neoadjuvant effect on the tumor and the improvement of approaches to drug therapy regimens allowed to significantly increase the relapse-free survival in this category of patients.
Key words: locally advanced rectal cancer, chemo radiotherapy, induction chemotherapy, consolidation chemotherapy, sandwich therapy
For citation: Polynovsky AV, Kuzmichev DV, Mamedli ZZ, Tkachev SI, Chernykh MV, Suraeva YuE, Madyarov ZhM, Aniskin AA, Kolobanov ES. Role of Intensification of Neoadjuvant Treatment of Patients with Locally Expanded Rectal Cancer. Medical Radiology and Radiation Safety 2021;66(5):50-58.
DOI: 10.12737/1024-6177-2021-66-5-50-58
References
1. Jung K., Kim H., Park J., et al. Adjuvant Chemotherapy after Neoadjuvant Chemoradiation and Curative Resection for Rectal Cancer: is it Necessary for All Patients? // J. Surgical Oncology. 2015. V.111, No. 4. P. 439-444.
2. Bosset J.-F., Calais G., Mineur L., et al. Fluorouracil-Based Adjuvant Chemotherapy after Preoperative Chemoradiotherapy in Rectal Cancer: Long-Term Results of the EORTC 22921 Randomised Study // Lancet Oncol. 2014. V.15, No. 2. P. 184–190.
3. Sainato A., Cernusco Luna Nunzia V., Valentini V., et al. No Benefit of Adjuvant Fluorouracil Leucovorin Chemotherapy after Neoadjuvant Chemoradiotherapy in Locally Advanced Cancer of the Rectum (LARC): Long Term Results of a Randomized Trial (I-CNR-RT) // Radiother Oncol. 2014. V.113, No. 2. P. 223–229.
4. Rödel C., Graeven U., Fietkau R., et al. Oxaliplatin Added to Fluorouracil-Based Preoperative Chemoradiotherapy and Postoperative Chemotherapy of Locally Advanced Rectal Cancer (the German CAO/ARO/AIO-04 Study): Final Results of the Multicentre, Open-Label, Randomised, Phase 3 Trial // Lancet Oncol. 2015. V.16, No. 8. P. 979–989.
5. Hong Y.S., Nam B.-H., Kim K.-P., et al. Oxaliplatin, Fluorouracil, and Leucov-Orin Versus Fluorouracil and Leucovorin as Adjuvant Chemotherapy for Locally Advanced Rectal Cancer after Preoperative Chemoradiotherapy (ADORE): an Open-Label, Multicentre, Phase 2, Randomised Controlled Trial // Lancet Oncol. 2014. V.15, No. 11. P. 1245–1253.
6. Schmoll H.J., Stein A., Hofheinz R.D., et al. Preoperative Chemoradiotherapy and Postoperative Chemotherapy with Capecitabine and Oxaliplatin vs. Capecitabine Alone in Locally Advanced Rectal Cancer: Final Analyses // Ann. Oncol. 2016. V.27 (suppl 6). Available at: https://academic.oup.com /annonc/article/ 27/suppl _ 6/467PD/2799263 Last Accessed November 21, 2019.
7. Hu X., Li Y.-Q., Li Q.-G., Ma Y.-L., Peng J.-J., Cai S.-J. Adjuvant Chemotherapy Seemed not to Have Survival Benefit in Rectal Cancer Patients with YpTis-2N0 after Preoperative Radiotherapy and Surgery from a Population-Based Propensity Score Analysis // Oncologist. 2019. V.24, No. 6. P. 803–811.
8. Fernandez-Martos C., Garcia-Albeniz X., Pericay C., et al. Chemoradiation, Surgery and Adjuvant Chemotherapy Versus Induction Chemotherapy Followed by Chemoradiation and Surgery: Long-Term Results of the Spanish GCR-3 Phase II Randomized Trial // Ann. Oncol. 2015. V.26, No. 8. P. 1722–1728.
9. Kim C.W., Kang B.M., Kim I.Y., et al. Korean Society of Coloproctology (KSCP) Trial of CONsolidation Chemotherapy for Locally Advanced Mid or Low Rectal Cancer after Neoadjuvant Concurrent Chemoradiotherapy: a Multicenter, Randomized Controlled Trial (KONCLUDE) // BMC Cancer. 2018. V.18, No. 1. P. 538.
10. Glynne-Jones R., Grainger J., Harrison M., et al. Neoadjuvant Chemotherapy Prior to Preoperative Chemoradiation or Radiation in Rectal Cancer: Should We Be More Cautious? // Br. J. Cancer. 2006. No. 94. P. 363-371.
11. Gao Y.H., Lin J.Z., An X. et al. Neoadjuvant Sandwich Treatment with Oxaliplatin and Capecitabine Administered Prior to, Concurrently with, and Following Radiation Therapy in Locally Advanced Rectal Cancer: a Prospective Phase 2 Trial // Int. J. Radiat. Oncol. Biol. Phys. 2014. V.90, No. 5. P. 1153–1160.
12. Landry J.C., Feng Y., Prabhu R.S., et al. Phase II Trial of Preoperative Radiation with Concurrent Capecitabine, Oxaliplatin, and Bevacizumab Followed by Surgery and Postoperative 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX), and Bevaci-zumab in Patients with Locally Advanced Rectal Cancer: 5-Year Clinical Outcomes ECOG-ACRIN Cancer Research Group E3204 // Oncologist. 2015. V.20, No. 6. Р. 615-616.
13. Maas M., Nelemans P.J., Valentini V., et al. Long-Term Outcome in Patients with a Pathological Complete Response after Chemoradiation for Rectal Cancer: a Pooled Analysis of Individual Patient Data // Lancet Oncol. 2010. V.11, No. 9. P. 835-844.
14. Habr-Gama A., Perez R.O., Nadalin W., Sabbaga J., Ribeiro U.Jr., Silva e Sousa A.H.Jr., Campos F.G., Kiss D.R., Gama-Rodrigues J. Operative Versus Nonoperative Treatment for Stage 0 Distal Rectal Cancer Following Chemoradiation Therapy: Long-Term Results // Ann. Surg. 2004. V.240, No. 4. P. 711–717. Discussion 717-718.
15. Petrelli F., Sgroi G., Sarti E., et al. Increasing the Interval Between Neoadjuvant Chemoradiotherapy and Surgery in Rectal Cancer: A Meta-Analysis of Published Studies // Ann. Surg. 2016. V.263, No. 3. Р. 458-464.
PDF (RUS) Full-text article (in Russian)
Conflict of interest. The author declare no conflict of interest.
Financing. The study had no sponsorship.
Contribution. Article was prepared with equal participation of the authors
Article received: 05.03.2021.
Accepted for publication: 29.04.2021.
Medical Radiology and Radiation Safety. 2021. Vol. 66. № 5. P. 59–65
Potential Possibilities of Nuclear Medicine Methods in Diagnostics Age Changes of the Cardiovascular System.
M.V. Vorontsova1, A.A. Obrezan 2, A.G. Obrezan 1,2
1JSC NOMECO, Saint-Petersburg, Russia
2Saint-Petersburg State University, Saint-Petersburg, Russia
Contact person: Andrei Andreevich Obrezan: This email address is being protected from spambots. You need JavaScript enabled to view it.
CONTENT
• Summary
• Introduction
• Structural and functional changes in the cardiovascular system during natural aging
• Methods for the study of age-related changes in the myocardium and large vessels used in clinical practice today
• The potential of nuclear medicine methods in the diagnosis of age-related changes in the cardiovascular system
• Conclusion
Key words: nuclear cardiology, radionuclide diagnostics, age changes, cardiovascular system, positron emission tomography
For citation: Vorontsova MV, Obrezan AA, Obrezan AG. Potential Possibilities of Nuclear Medicine Methods in Diagnostics Age Changes of the Cardiovascular System. Medical Radiology and Radiation Safety. 2021;66(5):59-65.
DOI: 10.12737/1024-6177-2021-66-5-59-65
References
1 Moskalev A.A., Shaposhnikov M.V., Soloviev I.A. Studying the geroprotective effects of inhibitors suppressing aging-associated signaling cascades in model organisms // Medical news of North Caucasis. 2017. 12. P. 342-347. DOI: 10.14300/mnnc.2017.12090. (in Russian)
2 Laurent S, Boutouyrie P, Guimarães Cunha P, Lacolley P, Nilsson PM. Concept of Extremes in Vascular Aging From Early Vascular Aging to Supernormal Vascular Aging // Hypertension. 2019. 74. P. 218-228. DOI: 10.1161/HYPERTENSIONAHA.119.12655.
3 Lishmanov Yu.B., Zavadovsky K.V., Efimova N.Yu., Krivonogov N.G., Efimova I.Yu., Vesnina Zh.V., Sazonova S.I., Saushkina Yu.V., Saushkin V.V., Ilyushenkova Yu.N., Gulya M.O., Peshkin Ya.A., Mochula A.V. PROSPECTS OF NUCLEAR MEDICINE FOR THE DIAGNOSIS OF CARDIOVASCULAR DISEASES // Siberian medical journal. 2015. 30(2). P. 21-29. https://doi.org/10.29001/2073-8552-2015-30-2-21-29. (in Russian)
4 Heron M. Deaths: leading causes for 2011 // Natl Vital Stat Rep. 2015. 64. P. 1-96.
5 Plokhova E.V., Akasheva D.U., Tkacheva O.N., Strazhesko I.D., Dudinskaya E.N., Kruglikova A.S., Pykhtina V.S., Agaltsov M.V., Sharashkina N.V., Brailova N.V., Skvortsov D.A., Boytsov S.A. Age-related remodeling of the left ventricular myocardium: is there a link with cellular aging? // Cardiovascular Therapy and Prevention, 2015. 14(2). P. 52–57. http://dx.doi.org/10.15829/1728-8800-2015-2-52-57. (in Russian)
6 Cuspidi C, Facchetti R, Sala C et al. Normal values of left-ventricular mass: echocardiographic findings from the PAMELA study // J Hypertens. 2012. 30(5). P. 997-1003. DOI: 10.1097/HJH.0b013e328352ac39.
7 Leibowitz D, Gilon D. Echocardiography and the Aging Heart // Current Cardiovascular Imaging Reports. 2012. 5(6). P. 501-506.
8 Shock NW, Greulich RC, Andres RA, et al. Normal human aging: the Baltimore Longitudinal Study of Aging. Bethesda, MD: NIH Pub No 84-2450; 1984.
9 Mendes AB, Ferro M, Rodrigues B, et al. Quantification of left ventricular myocardial collagen system in children, young adults, and the elderly // Medicina (B Aires). 2012. 72(3). P. 216-220. PMID: 22763158.
10 Blagova O.V., Nedostup A.V., Sedov V.P., Kogan E.A., Pasha S.P., Gagarina N.V., Alieva I.N., Sedov A.V., Tsaregorodtsev D.A., Kulikova V.A., Shepeleva N.E., Sarkisova N.D. Clinical Masks of Amyloidosis With the Heart Involvement: Modern Diagnostic Issues // Russian Journal of Cardiology. 2017. (2). P. 68-79. https: //doi.org/10.15829/1560-4071-2017-2-68-79. (in Russian.)
11 Damy T, Mohty D, Deux JF, et al. Senile systemic amyloidosis: Definition, diagnosis, why thinking about? // Presse Med. 2013. 42(6 Pt 1). P. 1003-14. doi: 10.1016/j.lpm.2013.03.004.
12 Groznova O.S., Miklashevich I.M., Voinova V.Yu., Shkolnikova M.A., Tkacheva O.N., Dudinskaya E.N., Kovalev I.A. Biomarkers of early cardiovascular aging // Ros Vestn Perinatol i Pediatr. 2019. 64:(4). P. 11-18. DOI: 10.21508/1027-4065-2019-64-4-11-18. (in Russian)
13 Strazhesko I.D., Akasheva D.U., Dudinskaya E.N., Tkacheva O.N. Vascular ageing: main symptoms and mechanisms // Cardiovascular Therapy and Prevention. 2012. 11(4). P. 93-100. https://doi.org/10.15829/1728-8800-2012-4-93-100. (in Russian)
14 Cunha P.G., Olsen M.H. Chapter 24. Vascular Aging and Cardiovascular Disease. In: Nilsson P.M., Olsen M.H., Laurent S., eds. Early Vascular Aging (EVA). New Directions in Cardiovascular Protection // Academic Press. 2015. P. 261-71. DOI:10.1016/B978-0-12-801387-8.00025-9.
15 Tesauro M, Mauriello A, Rovella V et al. Arterial ageing: from endothelial dysfunction to vascular calcification // J. Intern. Med. 2017. 281(5). P. 471–482. doi: 10.1111/joim.12605
16 Villa F., Carrizzo A., Spinelli C.C., Ferrario A., Malovini A., Maciąg A. et al. Genetic Analysis Reveals a Longevity-Asso- ciated Protein Modulating Endothelial Function and Angio- genesis // Circ Res. 2015. 117(4). P. 333–345. DOI: 10.1161/CIR- CRESAHA.117.305875
17 Sohn E.H., Flamme-Wiese M.J., Whitmore S.S., Wang K., Tucker B.A., Mullins R.F. Loss of CD34 expression in aging human choriocapillaris endothelial cells // PLoS One. 2014. 9(1). e86538. DOI: 10.1371/journal.pone.0086538.
18 Anthony J. Donato, Daniel R. Machin, Lisa A. Lesniewski. Mechanisms of Dysfunction in the Aging Vasculature and Role in Age-Related Disease // Circ Res. 2018. 123. P. 825-848. DOI: 10.1161/CIRCRESAHA.118.312563.
19 Laurent S., Boutouyrie P. Arterial Stiffness and Hypertension in the Elderly // Front. Cardiovasc. Med. 2020. 7:544302. doi: 10.3389/fcvm.2020.544302.
20 Ansheles A.A., Sergienko I.V., Sergienko V.B. Current State and Future Technologies of Nuclear Imaging in Cardiology // Kardiologiia. 2018. 58(6). P. 61-69. DOI: 10.18087/cardio.2018.6.10134. (in Russian)
21 Cheng S, Xanthakis V, Sullivan LM, et al. Correlates of Echocardiographic Indices of Cardiac Remodeling Over the Adult Life Course: Longitudinal Observations from the Framingham Heart Study // Circulation. 2010. 122(6). P. 570–578. doi: 10.1161/CIRCULATIONAHA.110.937821.
22 Pierdomenico SD, Di Nicola M, Pierdomenico AM, et al. Cardiovascular risk in subjects with left ventricular concentric remodeling at baseline examination: a meta-analysis // J. Hum. Hypertens. 2011. 25(10). P. 585-591. DOI: 10.1038/jhh.2011.24.
23 Carrick-Ranson G, Hastings JL, Bhella PS, et al. Effect of healthy aging on left ventricular relaxation and diastolic suction // Am. J. Physiol. Heart. Circ. Physiol. 2012. 303(3). P. 15-22. DOI: 10.1152/ajpheart.00142.2012.
24 John Eng, Robyn L. McClelland, Antoinette S. Gomes, et al. Adverse left Ventricular remodeling and age assessed with cardiac Mr imaging: The Multi-Ethnic Study of Atherosclerosis // Radiology. 2016. 278(3). P. 714-722. https://doi.org/10.1148/radiol.2015150982.
25 Reference Values for Arterial Stiffness’ Collaboration. Determinants of pulse wave velocity in healthy pe- ople and in the presence of cardiovascular risk factors: ‘establishing normal and reference values’ // Eur Heart J. 2010. 31(19). P. 2338–2350.
26 M. AlGhatrif, J.B. Strait, C.H. Morrell et al. Longitudinal trajectories of arterial stiffness and the role of blood pressure: the Baltimore Longitudinal Study of Aging // Hypertension. 2013. 62(5). P. 934-941. DOI: 10.1161/HYPERTENSIONAHA.113.01445.
27 Said MA, Eppinga RN, Lipsic E et al. Relationship of Arterial Stiffness Index and Pulse Pressure With Cardiovascular Disease and Mortality // J Am Heart Assoc. 2018. 7(2). URL: https://doi.org/10.1161 /JAHA.117.007621.
28 Lassale C, David Batty G, Steptoe A, Cadar D, Akbaraly TN, Kivimäki M, Zaninotto P. Association of 10-Year C-Reactive Protein Trajectories With Markers of Healthy Aging: Findings From the English Longitudinal Study of Aging // J Gerontol A Biol Sci Med Sci. 2019. 74(2). P. 195–203. https://doi.org/10.1093/gerona/gly028.
29 Ling LH., Kistler PM., EllimsAH., Iles LM., Lee G., Hughes GL., Kalman JM., Kaye DM., Taylor AJ. Diffuse ventricular fibrosis in atrial fibrillation: noninvasive evaluation and relationships with aging and systolic dysfunction // J. Am. Coll. Cardiol. 2012. 60. P. 2402–2408. DOI:10.1016/j.jacc.2012.07.065.
30 Bekmurzinova F.K., Ospanov O.B., Akilzhanova A.R., Kozhamkulov U.A., Rakhimova S.E. The evaluation of chromosome telomere length change as a criterion of life expectancy in bariatric practice // Obesity and metabolism. 2020. 17(2). P. 125-129. https://doi.org/10.14341 /omet1033. (in Russian)
31 Bressler J, Franceschini N, Demerath EW et al. Sequence variation in telomerase reverse transcriptase (TERT) as a determinant of risk of cardiovascular disease: the Atherosclerosis Risk in Communities (ARIC) study // BMC Med Genet. 2015. 16. P. 52. DOI: 10.1186/s12881-015-0194-x.
32 National guide to radionuclide diagnostics 2010. - Vol. 2. - 418 p. / ed. by Yu. B. Lishmanov, V. I. Chernov. - In 2 volumes-Tomsk : ISBN 980-5-93629-427-3.
33 A. Freund. Untangling Aging Using Dynamic, Organism-Level Phenotypic Networks // Cell Systems. 2019. 86. P. 172-181. https://doi.org /10.1016/j.cels.2019.02.005.
34 Sergienko V.B., Tereshchenko S.N., Ansheles A.A., Zhirov I.V., Safiullina A.A. Nuclear Imaging in the Diagnosis of Cardiac Amyloidosis // Rational Pharmacotherapy in Cardiology. 2018. 14(1). P. 94-100. DOI: 10.20996/1819-6446-2018-14-1-94-100. (in Russian)
35 Sergienko V.B., Ansheles A.A. Radionuclide diagnosis in cardiology. In: Chazov E.I., ed. Manual of cardiology. Volume 1. Moscow: Praktika. 2014. P. 571-612. (in Russian.)
36 Moghbel M., Al-Zaghal A., Werner T.J., Constantines- cu C.M., Høilund-Carlsen P.F., Alavi A. The role of pet in evaluating atherosclerosis: a critical review // Semin. Nucl. Med. 2018. 48(6). P. 488–497. DOI: 10.1053/j.sem- nuclmed.2018.07.001.
37 Karpova N.Yu., Rashid M.A., Kazakova T.V. et al. Calcific aortic stenosis: known facts and promising studies // The Clinician. 2020. 14(1–2). P. 34–41. DOI: 10.17650/1818-8338-2020-14-1-2-34-41. (in Russian.)
38 Ansheles A. A., Shigoleva Ya. V., Sergienko I. V., Tereshchenko S. N. SPECT myocardial perfusion and sympathetic innervation in patients with hypertrophic cardiomyopathy // Kardiologicheskij Vestnik. 2016. 11(1). P. 24-33. (in Russian.)
39 Chapman J., Fielder E., Passos J.F. Mitochon- drial dysfunction and cell senescence: deciphering a complex relationship // FEBS Lett. 2019. 593. P. 1566–1579. DOI: 10.1002/1873-3468.13498.
40 Korolchuk V.I., Miwa S., Carroll B., von Zglinicki T. Mitochondria in cell senescence: is mitophagy the weakest link? // EBio Medicine. 2017. 21. P. 7–13. DOI: 10.1016/j.ebiom.2017.03.020.
41 Safee ZM, Baark F, Waters ECT, et al. Detection of anthracycline induced cardiotoxicity using perfusioncorrected (99m)Tc sestamibi SPECT // Sci Rep. 2019. 9(1). P. 216. doi:10.1038/s41598018367215.
42 Ansheles A.A., Sergienko I.V., Prus Yu.A., Sergienko V.B. Nuclear imaging of chemotherapyinduced cardiotoxicity // Cardiovascular Therapy and Prevention. 2021. 20(2). P. 25-37. doi:10.15829/1728880020212537. (in Russian.)
43 Ferrucci L., Gonzalez-Freire M., Fabbri E., Simon- sick E., Tanaka T., Moore Z., Salimi S., Sierra F., de Cabo R. Measuring biological aging in humans: a quest // Aging Cell. 2020. 19. e13080. DOI: 10.1111/acel.13080.
44 Nilsson M.I., Tarnopolsky M.A. Mitochondria and aging-the role of exercise as a countermeasure // Biology. 2019. 8. P. 40. DOI: 10.3390/biology8020040.
45 Moro L. Mitochondrial dysfunction in aging and cancer // J. Clin. Med. 2019. 8. 1983. DOI: 10.3390/jcm8111983.
46 Sergienko VB. Modern possibilities of radionuclide molecular imaging of atherosclerosis // Atherosclerosis and Dyslipidemia. 2016. 4(25). P. 5-13. (in Russian)
47 Proshkina E.N., Solovev I.A., Shaposhnikov M.V., Moskalev A.A. Key molecular mechanisms of aging, biomarkers and potential interventions // Molecular biology. 2020. 54(6). P. 883–921. DOI: 10.31857/S002689 8420060099. (in Russian)
PDF (RUS) Full-text article (in Russian)
Conflict of interest. The author declare no conflict of interest.
Financing. The study had no sponsorship.
Contribution. Article was prepared with equal participation of the authors
Article received: 23.12.2020.
Accepted for publication: 20.01.2021.
Medical Radiology and Radiation Safety. 2021. Vol. 66. № 5. P. 78–84
Morbidity of Children's Population of Lermontov City, Located in the Uranium Legacy Area
Lyaginskaya A.M., Shandala N.K., Titov A.V., Metlyaev E.G., Kuptsov V.V., Karelina N.M.
A.I. Burnasyan Federal Medical Biophysical Center, Moscow, Russia
Contact person: YEvgeny Georgievich Metlyaev: This email address is being protected from spambots. You need JavaScript enabled to view it.
ABSTRACT
Purpose: To carry out assessment the health status of the child population of the Lermontov city. This child population living in the area, of uranium legacy, and they are critical group of the population in terms of sensitivity to adverse environmental factors.
Materials and methods: The object of the study was the morbidity of children 0–14 years old (primary, chronic, oncological). The research material was the data of reporting forms of medical statistics, presented in the following forms: 7 – information on malignant neoplasms and 12 - information on the number of diseases in children. The development included data from Clinical hospital # 101 of the FMBA of Russia for 2014–2018. Statistical data processing was carried out using standard methods used for the analysis of biomedical data.
Results: The morbidity of children 0–14 years old in Lermontov in 2014–2018 averaged 2310.9 ± 115.7 per 1000. In the structure of morbidity, the leading places were occupied by diseases of the respiratory system – 59.2 %, the digestive system – 8.8 %, skin and subcutaneous tissue 5.5 %, trauma and poisoning – 4, 8 % and infectious and parasitic diseases. The frequency of chronic morbidity does not exceed the population estimates – 73.0 ± 4.1 per 1000. The peculiarity of chronic morbidity is the relatively high incidence of skin diseases – 25.3 % and the musculoskeletal system – 20.4 %. The morbidity of children in the first year of life is 2348.0 ± 135.1 per 1000. A feature of the morbidity structure is the high incidence of respiratory diseases, which makes up 66.3 % of the total morbidity, with population estimates – 20–30 %.
Conclusion: The increased radiation background can be considered as one of the possible negative environmental factors affecting the health of the population.
Key words: morbidity, childhood, uranium legacy sites, critical population group, radon progeny
For citation: Lyaginskaya AM, Shandala NK, Titov AV, Metlyaev EG, Kuptsov VV, Karelina NM. Morbidity of Children's Population of Lermontov City, located in the Uranium legacy Area. Medical Radiology and Radiation Safety. 2021;66(5):78-84.
DOI: 10.12737/1024-6177-2021-66-5-78-84
References
1. Material from the free online encyclopedia - Wikipedia. Available at: https://ru.wikipedia.org/wiki/Лермонтов_(город) (Accessed 01 July 2020) (In Russian).
2. Titov AV, Shandala NK, Marenny AM et al. The radiation situation at the facility of the former LPO Almaz enterprise. Hygiene and Sanitation 2017; 96 (9); P. 822-826. (In Russian).
3. Assessment of the radioecological situation and environmental quality management in the regions where typical enterprises of the industry are located. Volume 1. Assessment of the radioecological situation and environmental quality management at the State Unitary Enterprise "Hydrometallurgical Plant" (HMP). M., 2001. (In Russian).
4. Titov AV, Shandala NK, Isaev DV, Semenova МP, Seregin VА, Belskikh YuS, Ostapchuk TV, Chernobaev AS. Assessment of the Public Radiation Protection and Economic Activity Safety in the Area of the Developed Uranium Deposit. Medical Radiology and Radiation Safety. 2020;65(2):11-16. (In Russian)
5. Report «On the state of sanitary and epidemiological well-being of the population in the city of Lermontov, Stavropol Territory in 2017». Analysis of activities for the section of work - radiation safety and occupational health for 2017. http://mru101 .fmbaros.ru/deyatelnost/sanitarno-epidemiologicheskoe-sostoyanie/ (Accessed 07 January 2020). (In Russian)
6. Marenny AM, Romanov VV, Astafurov VI, Gubin AT, Kiselev SM, Nefedov NA, Penezev AV. Carrying out surveys of buildings for various purposes for radon content in the territories served by FMBA of Russia. // Radiation Hygiene. 2015; 8 (1): 23-29.
7. ICRP, 2007. The 2007 Recommendations of the International Commission on Radiological Protection. ICRP Publication 103. Ann. ICRP 37 (2-4).
8. ICRP, 2014. Radiological Protection against Radon Exposure. ICRP Publication 126. Ann. ICRP 43(3).
9. ICRP, 2010. Lung Cancer Risk from Radon and Progeny and Statement on Radon. ICRP Publication 115, Ann. ICRP 40(1).
10. Merkov AM, Polyakov LE Guide for doctors. Sanitary statistic. “Medicine” Moscow, 1974.–384 p. (In Russian)
11. Unified system of control and accounting of individual radiation doses to citizens (ESKIF). Federal database of individual radiation doses for personnel of organizations and the population in the territories served by the FMBA of Russia and the Ministry of Defense of Russia. – М., 2012 – 86 p.
12. Merabishvili VM, Dyatchenko OT Dynamics of oncological morbidity and mortality in children (0–14) in St. Petersburg. J. Oncology Issues 2008 Vol.54 p. 272-280. (In Russian)
13. Schepin OP, Korotkikh RV, Schepin VO, Medic VA Public health is the foundation of health development; under the editorship of Schepin OP. – М., National Research Institute of Public Health, Russian Academy of Medical Sciences, 2009. – 376 p. (In Russian)
14. Ulumbekova GE Health care in Russia. Results of 2012-2016. Urgent measures in 2017-2018. Priorities of development until 2025. – М., ed. Group «GEOTAR-Media», 2017. 47 p. (In Russian)
PDF (RUS) Full-text article (in Russian)
Conflict of interest. The authors declare no conflict of interest.
Financing. The study had no sponsorship.
Contribution.
Research concept and design – Lyaginskaya A.M., Shandala N.K .., Titov A.V .;
Collection and processing of material – Lyaginskaya A.M., Shandala N.K .., Titov A.V., Metlyaev E.G .;
Text writing – V.V. Kuptsov Karelina N. M .;
Editing – Lyaginskaya A.M., Shandala N.K . Titov A.V.;
Approval of the final version of the article, responsibility for the integrity of all parts of the article – all co-authors
Article received: 16.03.2021.
Accepted for publication: 21.04.2021.
Medical Radiology and Radiation Safety. 2021. Vol. 66. № 5. P. 66–77
Topical Issues of Radiopharmaceuticals Appliance in PET Studies
A.V. Khmelev1,2
1Research Institute – Federal research Center for Project Evaluation and Consulting Services, Moscow, Russia
2Russian Medical Academy of Continuous Professional Education, Moscow, Russiaa
Contact person: Aleksandr Vasilyevich Khmelev: This email address is being protected from spambots. You need JavaScript enabled to view it.
CONTENT
Introduction
1. Requirements to radiopharmaceuticals
2. Factors affecting the biodistribution in organism
3. Uptake and localization mechanisms
4. Appliance in PET studies of biological processes and diagnostics
5. Aspects of regulation of radiopharmaceuticals circulation
Conclusion
Key words: radiopharmaceuticals, radionuclide, localization mechanism, PET
For citation: Khmelev AV. Topical Issues of Radiopharmaceuticals Appliance in PET StudiesSupport of Occupational Radiation Protection during. Medical Radiology and Radiation Safety. 2021;66(5):66-77.
DOI: 10.12737/1024-6177-2021-66-5-66-77
References
1.Vallabhajosula S. Molecular Imaging: Radiopharmaceuticals for PET and SPECT. Berlin, Heidelberg: Springer-Verlag, 2009. 133 p.
2. Saha G.B. Basics of PET Imaging. Physics, Chemistry and Regulation. New York, Springer, 2010. 241 p.
3. Khmelev А.V. Positron Emission Tomography: Physical and Technical Aspects. Мoscow, Trovant Publ., 2016. 336 p. (In Russ.).
4. Zimmermann R.G. Industrial Constraints in the Selection of Radionuclides and the Development of New Radiopharmaceuticals. World J. Nucl. Med. 2008;7:126-34.
5. Qaim M. Development of Cyclotron Radionuclides for Medical Applications: from Fundamental Nuclear Data to Sophisticated Production Technology. In: WTTC15: Proceedings of WTTC15; 2014 Aug 18-21. Prague, Czech Republic Publ., 2014. P. 18-20.
6. Khmelev А.V. Analysis of Positron Emission Tomography Providing with Radionuclides. Medical Radiology and Radiation Safety. 2019;64;6:70-81. (In Russ).
7. Kodina G.E., Krasikova R.N. Methods of Production of Radiopharmaceuticals and Radionuclide Generators for Nuclear Medicine. Мoscow, Izdat. Dom MEI Publ., 2014. 282 p. (In Russ.).
8. Davidson C.D., Phenix C.P., Tai T.C., Khaper N., Lees S.J. Searching for Novel PET Radiotracers: Imaging Cardiac Perfusion, Metabolism and Inflammation. Am. J. Nucl. Med. Mol. Imaging. 2018;8;3:200-27. PMID: 30042871. PMCID: PMC6056242.
9. Wadsak W., Mitterhauser M. Basic and Principles of Pharmaceuticals for PET/CT. E.J.R. 2010;73:461-469. DOI: 10.1016/j.ejrad.2009.12.022. PMID: 20181453.
10. Miller P.W., Long N.J., Vilar R., Gee A.D. Synthesis of 11C, 18F, 15O and 13N Radiolabels for Positron Emission Tomography. Angew. Chem. Int. Ed. 2008;47:8998-9033. DOI: 10.1002/anie.200800222. PMID: 18988199.
11. Zimmermann R.G. Why Are Investors not Interested in My Radiotracer? The Industrial and Regulatory Constraints in the Development of Radiopharmaceuticals. Nucl. Med. Biol. 2013;40:155-166. DOI: 10.1016/j.nucmedbio.2012.10.012. PMID: 23218796.
12. Lau J., Rousseau E., Kwon D., Lin K.-S., Bénard F., Chen X. Insight Into the Development of PET Radiopharmaceuticals for Oncology. Cancers. 2020;12;5:1312-1365. DOI: 10.3390/cancers12051312. PMID: 32455729. PMCID: PMC7281377.
13. Mourtada F., Sims-Mourtada J., Azhdarinia A., Yang D.J. Regulatory Requirements for PET Radiopharmaceuticals Production: Is Automation an Answer? Current Medical Imaging. 2008;4;1:28-33. DOI: 10.2174/157340508783502804.
14. Vallabhajosula S., Killeen R.P. Osborne J.R. Altered Biodistribution of Radiopharmaceuticals: Role of Radiochemical/Pharmaceutical Purity, Physiological, and Pharmacologic Factors. Semin. Nucl. Med. 2010;40:220-241. DOI: 10.1053/j.semnuclmed.2010.02.004 PMID: 20513446.
15. Ziessman H., O'Malley J. Nuclear Medicine: the Requisites. Philadelphia, Saunders, 2014. 464 p.
16. Kamkaew A., Ehlerding E.B., Cai W. Nanoparticles as Radiopharmaceutical Vectors. Radiopharmaceutical Chemistry. Eds. Lewis J., Windhorst A., Zeglis B. New York, Springer, Cham, 2019. P. 181-203.
17. Lee Y.S. Radiopharmaceuticals for Molecular Imaging. The Open Nuclear Medicine Journal. 2010;2:178-185.
18. Jeong J.M. Application of a Small Molecule Radiopharmaceutical Concept to Improve Kinetics. Nucl. Med. Mol. Imaging. 2016;50:99-101. DOI: https://doi.org/10.1007/s13139-015-0369-6.
19. Waterhouse R.N. Determination of Lipophilicity and Its Use as a Predictor of Blood-Brain Barrier Penetration of Molecular Imaging Agents. Mol. Imaging. Biol. 2003;5;6: 376-89. DOI: 10.1016/j.mibio. 2003.09.014 PMID: 14667492.
20. Silindir M., Özer A.Y. Recently Developed Radiopharmaceuticals for Positron Emission Tomography (PET). Fabad. J. Pharm. Sci. 2008;33:153-62.
21. Colom M., Vidal B., Zimmer L. Is there a Role for GPCR Agonist Radiotracers in PET Neuroimaging? Front. Mol. Neurosci. 2019;12:255-94. DOI: 10.3389/fnmol.2019.00255. PMID: 31680859. PMCID: PMC6813225.
22. Komal S., Nadeem S., Faheem Z., Raza A., Sarwer K., Umer H., et al. Localization Mechanisms of Radiopharmaceuticals. 2020. Available from: https://www.intechopen.com/online-first/localization-mechanisms-of-radiopharmaceuticals. DOI:10.5772/intechopen.94099.
23. Ponto J.A. Mechanisms of Radiopharmaceutical Localization. Ed. Norenberg J. UNM Сollege of pharmacy. 2012;16;4:2-35.
24. Lim M.M.D., Gnerre J., Gerard P. Mechanisms of Uptake of Common Radiopharmaceuticals. RadioGraphics Fundamentals |Online Presentation. Radiographics. 2018;38;5:1550-51. Available from: https://doi.org/10.1148/rg.2018180072
25. Kilian K. 68Ga-DOTA and Analogs: Current Status and Future Perspectives. Rep. Pract. Oncol. Radiother. 2014;19:13-21. DOI: 10.1016/j.rpor.2014.04.016. PMID: 28443194.
26. Huang Y.Y. An Overview of PET Radiopharmaceuticals in Clinical Use: Regulatory, Quality and Pharmacopeia Monographs of the United States and Europe. 2018. Available from: https:// www.intechopen.com /books/nuclear-medicine-physics/an-overview-of-pet-radio pharmaceuticals-in-clinical-use-regulatory-quality-and-pharmacopeia-monograp. DOI:10.5772/intechopen.79227.
27. Perk L.R., Stigter-van Walsum M., Visser G.W., Kloet R.W., Vosjan M.J.W.D., Leemans C.R., et al. Quantitative PET Imaging of Met-Expressing Human Cancer Xenografts with 89Zr-Labelled Monoclonal Antibody DN30. Eur. J. Nucl. Med. Mol. Imaging. 2008;35:1857-1867. Available from: https://doi.org/10.1007/s00259-008-0774-5.
28. Brooks A.F., Drake L.R., Stewart M.N., Cary B.P., Jackson I.M., Mallette D., et al. Fluorine-18 Patents (2009–2015). Part 1. Novel Radiotracers. Pharm. Pat. Anal. 2016;5;1:17-47. DOI: 10.4155/ppa.15.36. PMID: 26670619. PMCID: PMC5561792.
29. Pagani M., Stone-Elander S., Larsson S.A. Alternative Positron Emission Tomography with Non-Conventional Positron Emitters: Effects of Their Physical Properties on Image Quality and Potential Clinical Applications. Eur. J. Nucl. Med. 1997;24;10:1301-1327. DOI: 10.1007/s00259 0050156. PMID: 9323273.
30. Jødal L., Le Loirec С., Champion С. Positron Range in PET Imaging: Non-Conventional Isotopes. Physics in Medicine and Biology. IOP Publishing. 2014;59:7419-34. Available from: https://www.hal.archives-ouvertes.fr/hal-01174227.
31. Jung J., Ahn B.-C. Current Radiopharmaceuticals for Positron Emission Tomography of Brain Tumors. Brain Tumor Res Treat. 2018;6;2:47-53. DOI: 10.14791/btrt.2018.6.e13.PMID: 30381916. PMCID: PMC62 12689.
32. Zykov E.M., Pozdnyakov A.V., Kostenikov N.A. Efficient Use of PET and PET/CT in Oncology. Practical Oncology. 2014;15;1:31-6 (In Russ.).
33. Lopci E., Grassi I., Chiti A., Nanni C., Cicoria G., Toschi L., et al. PET Radiopharmaceuticals for Imaging of Tumor Hypoxia: a Review of the Evidence. Am. J. Nucl. Med. Mol. Imaging. 2014;4;4:365-384. PMID: 24982822. MCID: PMC4074502.
34. Andersson J.D., Halldin C. PET Radioligands Targeting the Brain GABAA/Benzodiazepine Receptor Complex. J. Label. Compd. Radiopharm. 2013;56:196-206. DOI: 10.1002/jlcr.3008. PMID: 24285326.
35. Meisenheimer M., Saenko Yu., Eppard E. Gallium-68: Radiolabeling of Radiopharmaceuticals for PET Imaging- a Lot to Consider. 2019. Available from: https://www.intechopen.com/books/medical- isotopes/gallium-68-radiolabeling-of-radiopharmaceuticals-for-pet-imaging-a-lot-to-consider. IntechOpen. DOI: 10.5772/intechopen.90615.
36. Weineisen M., Schottelius M., Simecek J., Baum R.P., Yildiz .A., Beykan S., et al. 68Ga- and 177Lu-labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human Studies. J. Nucl. Med. 2015;56;8:1169-1176. PMID: 26089548. DOI: 10.2967/jnumed.115.158550.
37. Werner R.A., Bluemel C., Allen-Auerbach M.S., Higuchi T., Hermann R. 68Gallium- and 90Yttrium-/ 177Lutetium: “Theranostic Twins” for Diagnosis and Treatment of NETs. Ann. Nucl. Med. 2015;29:1-7. DOI: https://doi.org/10.1007/s12149-014-0898-6.
38. van de Watering F.C.J., Rijpkema M., Perk L., Brinkmann U., Oyen W.J.G., Boerman O.C., et al. Zirconium-89 Labeled Antibodies: a New Tool for Molecular Imaging in Cancer Patients. Biomed. Res. Int. 2014;2014;203601. DOI: 10.1155/2014/203601. PMID: 24991539.
39. Dijkers E.C., Kosterink J.G., Rademaker A.P., Perk L.R., van Dongen G.A.M.S., Bart J., et al. Development and Characterization of Clinical-Grade 89Zr-Trastuzumab for HER2/New ImmunoPET Imaging. J. Nucl. Med. 2009 50:974-981. PMID: 19443585 DOI: 10.2967/jnumed.108. 060392.
40. Mahajan S., Divgi C.R. The Role of Iodine-124 Positron Emission Tomography In Molecular Imaging. Clin Transl Imaging. 2016;4;4:297-306. PMID: 27158012. DOI: 10.1016/j.cpet.2008.05.001.
41. FDA-Approved Radiopharmaceutical. Cardinal Health. 2019. Rev. 21/6.26.20. Available from: https://www.cardinalhealth.com/content/ dam/corp/web/documents/fact-sheet/cardinal-health-fda-approved-radiopharmaceuticals.pdf.
42. Clarke B.N. PET Radiopharmaceuticals: what’s New, what’s Reimbursed, what’s Next? J. Nucl. Med. Tech. 2018;46;1:12-16. PMID: 29438008. DOI: 10.2967/jnmt.117.205021.
43. Zelinskaya E. Radiopharmacy – Unique Trending of Pharmaceutic Industry. GMP News. 2018;2;16:55-70 (In Russian).
PDF (RUS) Full-text article (in Russian)
Conflict of interest. The author declare no conflict of interest.
Financing. The study had no sponsorship.
Contribution. Article was prepared with equal participation of the authors
Article received: 23.12.2020.
Accepted for publication: 20.01.2021.
Medical Radiology and Radiation Safety. 2021. Vol. 66. № 5. P. 85–90
Cancer Registry of Population in the City Ozyorsk:
Structure of Malignant Neoplasms First Diagnosed in Period From 1948 to 2016
P.V. Okatenko1, E.P. Fomin2, E.V. Denisova1, I.S. Kuznetsova1, M.E. Sokolnikov1, N.A. Koshurnikova1
1 Southern Urals Biophysics Institute FMBA, Ozyorsk, Russia
2 Clinical Hospital №71 FMBA, Ozyorsk, Russia
Contact person: Pavel Viktorovich Okatenko: This email address is being protected from spambots. You need JavaScript enabled to view it.
ABSTRACT
Purpose: The analysis of the structure of malignant neoplasms (MN) incidence among the population in the city Ozyorsk, located near Mayak Production Association, based on the information from the territorial cancer registry.
Materials and methods: There were 14681 first diagnosed cases of malignant neoplasms at the period from 1948 to 2016 in the territorial cancer registry of Ozyorsk. The diagnoses were verified by all available medical documents.
The structure of MN incidence, vital status of diseased people, age in a year of diagnostics, rank distribution of the basic localizations were studied.
Results: For 70 years period of follow-up there were 7676 cases from 14681 of MN incidence cases during the last 17 years (from 2000 to 2017) – as much as for the previous 51 years of follow-up from 1948 to 1999 (7005 cases). In the MN structure solid cancer constitutes 94.5 %, hemoblastoses – 5.5 %. As at December 31, 2016 23.3 % of the diseased people were alive, 75.2 % died from all causes, 1.5 % lost to follow-up. The cause of 80,6 % deaths was MN. Age in the year of diagnostics constitutes 61,7 years. 75.8 % diagnoses have morphological confirmation. During the entire period of follow-up first three places belong to lung cancer, gastric cancer and prostate cancer for males; breast cancer, gastric cancer and colon cancer for females in the MN structure.
Conclusions: During the period from 1948 to 2016 the growth of the first diagnosed MN cases among the population of Ozyorsk was a result of the population doubling and a fourfold increase of the citizens over the age of 50. Developed and supported cancer registry allows to analyze and partially control oncological situation in the closed cities of Rosatom.
Key words: cancer-registry, Mayak PA, Ozyorsk, population, malignant neoplasm
For citation: Okatenko PV, Fomin EP, Denisova EV, Kuznetsova IS, Sokolnikov ME, Koshurnikova NA. Cancer Registry of Population in the City Ozyorsk: Structure of Malignant Neoplasms First Diagnosed in Period From 1948 to 2016. Medical Radiology and Radiation Safety. 2021;66(5):85-90.
DOI: 10.12737/1024-6177-2021-66-5-85-90
References
1. A Review of Human Carcinogens. Part D: Radiation. Lyon, France, IARC, 2012. 363 p.
2. Ed. Kiselev M.F., Shandala N.K. ICRP Publication 103. Moscow, Alana Publ., 2009. 344 p. (In Russ.).
3. Vazhenin A.V., Domozhirova A.S., Aksenova I.A., et al. Epidemiological Peculiarities of the Oncological Situation and Health Status Indicators of the Oncological Care Among the Population of Chelyabinsk Region in 2018. Chelyabinsk Publ., 2018. 60 p. (In Russ.).
4. Cancer Registration: Principles and Methods. Lyon, France, IARC, 1991. 169 p.
5. Zielinski J.M., Shilnikova N.S., Krewski D. Canadian National Dose Registry of Radiation Workers: Overview of Research from 1951 through 2007. Int. J. Occup. Med. Environ Health. 2008;21;4:269-75.
6. Haylock R.G.E., Gillies M., Hunter N., et al. Cancer Mortality and Incidence Following External Occupational Radiation Exposure: an Update of the 3rd Analysis of the UK National Registry for Radiation Workers. British Journal of Cancer. 2018;119:631–637.
7. Hunter N., Harrison J.D., Kuznetsova I.S., Labutina E.V. Solid Cancer Incidence other than Lung, Liver and Bone in Mayak Workers: 1948-2004. Br. J. Cancer. 2013;109;7:1989-1996.
8. Labutina E.V., Kuznetsova I.S., Hunter N., et al. Radiation Risk of Malignant Neoplasms in Organs of Main Deposition for Plutonium in the Cohort of Mayak Workers with Regard to Histological Types. Health Phys. 2013;105;2:165-76.
9. Kuznetsova I.S., Labutina E.V., Hunter N. Radiation Risks of Leukemia, Lymphoma and Multiple Myeloma Incidence in the Mayak Cohort: 1948-2004. PLoS ONE. 2016;11;9:1-14.
10. Novoselov V.N., Nosach Yu.F., Entyakov B.N. Atomic Heart of Russia. Chelyabinsk, Avtograf Publ., 2014. 528 p. (In Russ.).
11. Fomin E.P., Okatenko P.V., Koshurnikova N.A. Malignant Neoplasms Incidence among Ozersk Population During the Period 1948-2005. Medical Radiology and Radiation Safety. 2007;52;6:29-34 (In Russ.).
12. Tretyakov F.D., Romanov S.A., Prishchepova M.S., Ryzhov V.P. Demographic Situation in the City Ozersk. Ozersk Publ., 2007. 32 p. (In Russ.).
13. Malignant Neoplasms in Russia. http://www.oncology.ru/service/statistics/malignant_tumors/ (In Russ.).
14. Merkov A.M., Polyakov L.E. Sanitary Statistics. Moscow, Meditcine Publ., 1974. 384 p. (In Russ.).
PDF (RUS) Full-text article (in Russian)
Conflict of interest. The authors declare no conflict of interest.
Financing. The study had no sponsorship.
Contribution. Article was prepared with equal participation of the authors.
Article received: 23.12.2020.
Accepted for publication: 20.01.2021.